{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:04:59Z","timestamp":1789923899023,"version":"4.0.1"},"reference-count":35,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2015.0320","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:24:09Z","timestamp":1525253049000},"source":"Crossref","is-referenced-by-count":15,"title":["Secondary Malignancies Following Treatment for Hodgkin\u2019s Lymphoma in Childhood and Adolescence"],"prefix":"10.3238","author":[{"given":"Wolfgang","family":"D\u00f6rffel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Riepenhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"L\u00fcders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Br\u00e4mswig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Schellong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2015,5,1]]},"reference":[{"key":"10.3238\/arztebl.2015.0320_ref1","doi-asserted-by":"crossref","unstructured":"G\u00f6bel U, Fischer R, Henze G: Von der Therapiestudie zur Qualit\u00e4tssicherung in der P\u00e4diatrischen Onkologie. Klin Padiatr 1997; 209: 145\u20136","DOI":"10.1055\/s-2008-1043967"},{"key":"10.3238\/arztebl.2015.0320_ref2","unstructured":"Donaldson SS, Kaplan H: Complications of treatment of Hodgkin\u2019s disease in children. Cancer Treatm Rep 1982; 66: 977\u201389"},{"key":"10.3238\/arztebl.2015.0320_ref3","doi-asserted-by":"crossref","unstructured":"Schellong G, Riepenhausen M: Late effects after therapy of Hodgkin\u2019s disease: Update 2003\/04 on overwhelming post-splenectomy infections and secondary malignancies. Klin P\u00e4diatr 2004; 216: 364\u20139","DOI":"10.1055\/s-2004-832340"},{"key":"10.3238\/arztebl.2015.0320_ref4","unstructured":"D\u00f6rffel W, Riepenhausen M, Ludwig WD, Schellong G: Langzeitfolgen nach Therapie eines Hodgkin-Lymphoms bei Kindern und Jugendlichen. Journalonko 2010; 10: 449\u201356."},{"key":"10.3238\/arztebl.2015.0320_ref5","doi-asserted-by":"crossref","unstructured":"Schellong G: Treatment of children and adolescents with Hodgkin\u2019s disease: the experience of the German-Austrian Paediatric Study Group. Bailli\u00e8re\u2019s Clin Haemat 1996; 9: 619\u201334","DOI":"10.1016\/S0950-3536(96)80030-8"},{"key":"10.3238\/arztebl.2015.0320_ref6","doi-asserted-by":"crossref","unstructured":"D\u00f6rffel W, R\u00fchl U, L\u00fcders H, et al.: Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: Final results of the multinational trial GPOH-HD 95. J Clin Oncol 2013; 31: 1562\u20138","DOI":"10.1200\/JCO.2012.45.3266"},{"key":"10.3238\/arztebl.2015.0320_ref7","doi-asserted-by":"crossref","unstructured":"L\u00fcders H, R\u00fchl U, Marciniak H, et al.: The impact of central review and central therapy planning on the treatment of children and adolescents with Hodgkin lymphoma. Eur J Cancer 2014; 50: 425\u201333","DOI":"10.1016\/j.ejca.2013.09.017"},{"key":"10.3238\/arztebl.2015.0320_ref8","doi-asserted-by":"crossref","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695\u2013706","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O"},{"key":"10.3238\/arztebl.2015.0320_ref9","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457\u201381","DOI":"10.1080\/01621459.1958.10501452"},{"key":"10.3238\/arztebl.2015.0320_ref10","doi-asserted-by":"crossref","unstructured":"Travis LB: Evaluation of the risk of therapy-associated complications in survivors of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2007: 192\u20136","DOI":"10.1182\/asheducation-2007.1.192"},{"key":"10.3238\/arztebl.2015.0320_ref11","doi-asserted-by":"crossref","unstructured":"Schellong G, Riepenhausen M, Ehlert K, et al.: Breast cancer in young women after treatment for Hodgkin\u2019s lymphoma during childhood or adolescence \u2013 an observational study with up to 33-year follow up. Dtsch Arztebl Int 2014; 111: 3\u20139","DOI":"10.3238\/arztebl.2014.0003"},{"key":"10.3238\/arztebl.2015.0320_ref12","doi-asserted-by":"crossref","unstructured":"Neglia JP, Friedmann DL, Yasui Y, et al.: Second malignant neoplasms in five-year survivors of childhood cancer: Childhood Cancer Survivor Study. J Natl Cancer Inst 2001; 93: 618\u201329","DOI":"10.1093\/jnci\/93.8.618"},{"key":"10.3238\/arztebl.2015.0320_ref13","doi-asserted-by":"crossref","unstructured":"Friedmann DL, Whitton J, Leisenring W, et al.: Subsequent neoplasms in 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study. J Natl Cancer Inst 2010; 102: 1083\u201395","DOI":"10.1093\/jnci\/djq238"},{"key":"10.3238\/arztebl.2015.0320_ref14","doi-asserted-by":"crossref","unstructured":"Sankila R, Garwicz S, Olsen JH, et al.: For the Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology: Risk of subsequent malignant neoplasms among 1641 Hodgkin\u2019s disease patients diagnosed in childhood and adolescence: A population-based cohort study in the five Nordic countries. J Clin Oncol 1996; 14: 1442\u20136","DOI":"10.1200\/JCO.1996.14.5.1442"},{"key":"10.3238\/arztebl.2015.0320_ref15","doi-asserted-by":"crossref","unstructured":"Wolden SL, Lamborn KR, Cleary SF, Tate DJ, Donaldson SS: Second cancers following pediatric Hodgkin\u2019s disease. J Clin Oncol 1998; 16: 536\u201344","DOI":"10.1200\/JCO.1998.16.2.536"},{"key":"10.3238\/arztebl.2015.0320_ref16","doi-asserted-by":"crossref","unstructured":"Green DM, Hyland A, Barcos MP, et al.: Second malignant neoplasms after treatment for Hodgkin\u2019s disease in childhood or adolescence. J Clin Oncol 2000; 18: 1492\u20139","DOI":"10.1200\/JCO.2000.18.7.1492"},{"key":"10.3238\/arztebl.2015.0320_ref17","doi-asserted-by":"crossref","unstructured":"Metayer C, Lynch CF, Clarke EA, et al.: Second cancers among long-term survivors of Hodgkin\u2019s disease diagnosed in childhood and adolescence. J Clin Oncol 2000; 18: 2435\u201343","DOI":"10.1200\/JCO.2000.18.12.2435"},{"key":"10.3238\/arztebl.2015.0320_ref18","doi-asserted-by":"crossref","unstructured":"Bhatia S, Yasui Y, Robison LL, et al.: High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin\u2019s disease: Report from the Late Effects Study Group. J Clin Oncol 2003; 21: 4386\u201394","DOI":"10.1200\/JCO.2003.11.059"},{"key":"10.3238\/arztebl.2015.0320_ref19","doi-asserted-by":"crossref","unstructured":"Constine LS, Tarbell N, Hudson MM, et al.: Subsequent malignancies in children treated for Hodgkin\u2019s disease: Associations with gender and radiation dose. Int J Radiation Oncology Biol Phys 2008; 72: 24\u201333","DOI":"10.1016\/j.ijrobp.2008.04.067"},{"key":"10.3238\/arztebl.2015.0320_ref20","doi-asserted-by":"crossref","unstructured":"O\u2019Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP: Second malignant neoplasms in survivors of pediatric Hodgkin\u2019s lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol 2010; 28: 1232\u20139","DOI":"10.1200\/JCO.2009.24.8062"},{"key":"10.3238\/arztebl.2015.0320_ref21","doi-asserted-by":"crossref","unstructured":"van Leeuwen FE, Klokman J, van\u2019t Veer MB, et al.: Long-term risk of second malignancy in survivors of Hodgkin\u2019s disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18: 487\u201397","DOI":"10.1200\/JCO.2000.18.3.487"},{"key":"10.3238\/arztebl.2015.0320_ref22","doi-asserted-by":"crossref","unstructured":"Hodgson DC, Gilbert ES, Dores GM, et al.: Long-term solid cancer risk among 5-year survivors of Hodgkin\u2019s lymphoma. J Clin Oncol 2007; 25: 1489\u201397","DOI":"10.1200\/JCO.2006.09.0936"},{"key":"10.3238\/arztebl.2015.0320_ref23","doi-asserted-by":"crossref","unstructured":"Ng AK, Kenney LB, Gilbert ES, Travis LB: Secondary malignancies across the age spectrum. Semin Radiat Oncol 2010; 20: 67\u201378","DOI":"10.1016\/j.semradonc.2009.09.002"},{"key":"10.3238\/arztebl.2015.0320_ref24","doi-asserted-by":"crossref","unstructured":"Omer B, Kadan-Lottick NS, Roberts KB, et al.: Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. Br J Haematol 2012, 158: 615\u201325","DOI":"10.1111\/j.1365-2141.2012.09211.x"},{"key":"10.3238\/arztebl.2015.0320_ref25","doi-asserted-by":"crossref","unstructured":"Travis LB, Gospodarowicz M, Curtis RE, et al.: Lung cancer following chemotherapy and radiotherapy for Hodgkin\u2019s disease. J Natl Cancer Inst 2002; 94: 182\u201392","DOI":"10.1093\/jnci\/94.3.182"},{"key":"10.3238\/arztebl.2015.0320_ref26","doi-asserted-by":"crossref","unstructured":"Schellong G, Riepenhausen M, Creutzig U, et al.: Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin\u2019s disease. J Clin Oncol 1997; 25: 2241\u201353","DOI":"10.1200\/JCO.1997.15.6.2247"},{"key":"10.3238\/arztebl.2015.0320_ref27","doi-asserted-by":"crossref","unstructured":"Inskip PD: Thyroid cancer after radiotherapy for childhood cancer. Med Pediatr Oncol 2001; 36: 568\u201373","DOI":"10.1002\/mpo.1132"},{"key":"10.3238\/arztebl.2015.0320_ref28","doi-asserted-by":"crossref","unstructured":"Acharya S, Sarafoglou K, LaQuaglia M, et al.: Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence. Cancer 2003; 97: 2397\u2013403","DOI":"10.1002\/cncr.11362"},{"key":"10.3238\/arztebl.2015.0320_ref29","doi-asserted-by":"crossref","unstructured":"Sigurdson AJ, Ronkers CM, Mertens AC, et al.: Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet 2005; 365: 2014\u201323","DOI":"10.1016\/S0140-6736(05)66695-0"},{"key":"10.3238\/arztebl.2015.0320_ref30","doi-asserted-by":"crossref","unstructured":"Bhatti P, Veiga LHS, Ronkers CM, et al.: Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: An update from the Childhood Cnacer Survivor Study. Radiat Res 2010; 174: 741\u201352 MEDLINE","DOI":"10.1667\/RR2240.1"},{"key":"10.3238\/arztebl.2015.0320_ref31","doi-asserted-by":"crossref","unstructured":"Choi DK, Helenowski I, Hijya N: Secondary malignancies in pediatric cancer survivors: Perspectives and review of the literature. Int J Cancer 2014; 135: 1764\u201373","DOI":"10.1002\/ijc.28991"},{"key":"10.3238\/arztebl.2015.0320_ref32","doi-asserted-by":"crossref","unstructured":"Oeffinger KC, Baxi SS, Friedman DN, Moskowitz CS: Solid tumor second primary neoplasms: Who is at risk, what can we do? Semin Oncol 2013; 40: 676\u201389","DOI":"10.1053\/j.seminoncol.2013.09.012"},{"key":"10.3238\/arztebl.2015.0320_ref33","doi-asserted-by":"crossref","unstructured":"Best T, Li D, Skol D: Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin lymphoma. Nat Med 2011; 17: 941\u20133","DOI":"10.1038\/nm.2407"},{"key":"10.3238\/arztebl.2015.0320_ref34","doi-asserted-by":"crossref","unstructured":"Nichols KE, Heath JA, Friedman D, et al.: TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin\u2019s disease with second primary neoplasms. J Clin Oncol 2003; 21: 4505\u20139","DOI":"10.1200\/JCO.2003.12.042"},{"key":"10.3238\/arztebl.2015.0320_ref35","doi-asserted-by":"crossref","unstructured":"Mertens AC, Mitby PA, Radloff G, et al.: XRCC1 and glutathione-S-transferase gene polymorphisms and susceptibility to radiotherapy-related malignancies in survivors of Hodgkin disease. A report from the Childhood Cancer Survivor Study. Cancer 2004; 101: 1463\u201372","DOI":"10.1002\/cncr.20520"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2015.0320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T13:38:16Z","timestamp":1638797896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2015.0320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,1]]},"references-count":35,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2015.0320","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,1]]}}}